Genetic Insights on ADRB1 and ADRB2 Targets for Clear Cell Renal Cell Carcinoma

Finnish cohorts of 752,817 and 315,137 individuals were used in a Mendelian randomization study to investigate the association between antihypertensive drug targets and clear cell renal cell carcinoma (CCRCC) risk. The dataset, authored by Honghui Zhu and last updated in June 2026, contains summary statistics from genome-wide association studies (GWAS) and colocalization analyses. It identifies ADRB1 and ADRB2 as potential genetic targets associated with increased CCRCC risk.

Use Cases

• Validate genetic associations between drug targets and cancer risk based on Mendelian randomization results.
• Perform colocalization analysis to identify shared genetic variation regions based on posterior probability (PP4) scores.
• Investigate the relationship between gene expression and tumor survival based on the described Western blotting and prognostic analyses.
• Conduct meta-analysis on genetic risk factors by integrating results from multiple cohorts as described in the study.

Strengths

• Analysis includes a large discovery cohort of 752,817 individuals and a validation cohort of 315,137 individuals.
• Provides specific odds ratios and confidence intervals (e.g., ADRB1 OR: 1.100; 95% CI: 1.066–1.135) for genetic associations.
• Results are supported by colocalization analyses with high posterior probabilities (e.g., ADRB1 PP4 = 0.996).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is presented in a 1.0 MB PDF, which may require extraction and structuring for computational analysis.

Provenance

Source

figshare, author Honghui Zhu.

Collection Method

Summary-data-based Mendelian randomization (SMR) and colocalization analyses performed on GWAS summary statistics.

Freshness

Last updated 2026-06-03 06:00:21; freshness should be verified.

Geography

Data derived from Finnish cohorts.